Antipsychotic-induced DRD2 upregulation and its prevention by α-lipoic acid in SH-SY5Y Neuroblastoma cells

Synapse

Volumn 65, Issue 4, 2011, Pages 321-331

  Deslauriers, Jessica ^a   Lefrançois, Marilou ^a   Larouche, Annie ^a   Sarret, Philippe ^a   Grignon, Sylvain ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Amisulpride; Dopamine; Haloperidol; Oxidative stress; Schizophrenia; SH SY5Y

Indexed keywords

AMISULPRIDE; BETA ACTIN; BIOLOGICAL MARKER; CATECHOLAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; MESSENGER RNA; METIROSINE; NEUROLEPTIC AGENT; SUPEROXIDE; THIOCTIC ACID;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; NEUROBLASTOMA CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; RECEPTOR UPREGULATION; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; NEUROBLASTOMA; RECEPTORS, DOPAMINE D2; THIOCTIC ACID; UP-REGULATION;

EID: 79251555954     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20851     Document Type: Article

References (56)

1. 2-induced upregulation of heme oxygenase-1 mRNA in H9c2 cells. Cell Signal 18: 1801-1812.
2. Agostinho FR, Jornada LK, Schroder N, Roesler R, Dal-Pizzol F, Quevedo J. 2007. Effects of chronic haloperidol and/or clozapine on oxidative stress parameters in rat brain. Neurochem Res 32: 1343-1350.
3. Balijepalli S, Kenchappa RS, Boyd MR, Ravindranath V. 2001. Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: Comparison with atypical antipsychotics. Neurochem Int 38: 425-435.
4. Beal MF. 1995. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38: 357-366.
5. Behl C, Rupprecht R, Skutella T, Holsboer F. 1995. Haloperidol-induced cell death-mechanism and protection with vitamin E in vitro. Neuroreport 7: 360-364.
6. Bernard V, Le Moine C, Bloch B. 1991. Striatal neurons express increased level of dopamine D2 receptor mRNA in response to haloperidol treatment: A quantitative in situ hybridization study. Neuroscience 45: 117-126.
7. Bontempi S, Fiorentini C, Busi C, Guerra N, Spano P, Missale C. 2007. Identification and characterization of two nuclear factor-κB sites in the regulatory region of the dopamine D2 receptor. Endocrinology 148: 2563-2570.
8. Brown K, Reid A, White T, Henderson T, Hukin S, Johnstone C, Glen A. 1998. Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia. Biol Psychiatry 43: 863-867.
9. Cadet JL. 1994. Free radicals and neurodegeneration. Trends Neurosci 17: 192-194.
10. Cadet JL, Lohr JB. 1989. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann NY Acad Sci 570: 176-185.
11. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A. 2004. Oxidative damage and schizophrenia: The potential benefit by atypical antipsychotics. Neuropsychobiology 49: 205-209.
12. Esterbauer H, Cheeseman KH. 1990. Determination of aldehydic lipid peroxidation products: Malonaldehyde and 4-hydroxynonenal. Methods Enzymol 186: 407-421.
13. Fachinetto R, Burger ME, Wagner C, Wondracek DC, Brito VB, Nogueira CW, Ferreira J, Rocha JB. 2005. High fat diet increases the incidence of orofacial dyskinesia and oxidative stress in specific brain regions of rats. Pharmacol Biochem Behav 81: 585-592.
14. 2 receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-κB. Mol Endocrinol 16: 353-366.
15. Gerard-Monnier D, Erdelmeier I, Regnard K, Moze-Henry N, Yadan JC, Chaudiere J. 1998. Reactions of 1-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals. Analytical applications to a colorimetric assay of lipid peroxidation. Chem Res Toxicol 11: 1176-1183.
16. Ghisi V, Ramsey AJ, Masri B, Gainetdinov RR, Caron MG, Salahpour A. 2009. Reduced D2-mediated signaling activity and trans-synaptic upregulation of D1 and D2 dopamine receptors in mice overexpressing the dopamine transporter. Cell Signal 21: 87-94.
17. Grignon S, Levy N, Couraud F, Bruguerolle B. 1996. Tyrosine kinase inhibitors and cycloheximide inhibit Li+ protection of cerebellar granule neurons switched to non-depolarizing medium. Eur J Pharmacol 315: 111-114.
18. Halliwell B. 1987. Oxidants and human disease: Some new concepts. Faseb J 1: 358-364.
19. Halliwell B. 2003. Oxidative stress in cell culture: An under-appreciated problem? FEBS Lett 540: 3-6.
20. Jia Z, Hallur S, Zhu H, Li Y, Misra HP. 2008. Potent upregulation of glutathione and NAD(P)H:quinone oxidoreductase 1 by alpha-lipoic acid in human neuroblastoma SH-SY5Y cells: Protection against neurotoxicant-elicited cytotoxicity. Neurochem Res 33: 790-800.
21. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS. 2002. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: A pharmacological analysis in rats. J Pharmacol Exp Ther 302: 1129-1134.
22. Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J, Ruther E, Emrich HM, Schneider U, Bleich S. 2005. Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsychiatry Clin Neurosci 17: 227-231.
23. Kume T, Kawato Y, Osakada F, Izumi Y, Katsuki H, Nakagawa T, Kaneko S, Niidome T, Takada-Takatori Y, Akaike A. 2008. Dibutyryl cyclic AMP induces differentiation of human neuroblastoma SH-SY5Y cells into a noradrenergic phenotype. Neurosci Lett 443: 199-203.
24. Kumer SC, Vrana KE. 1996. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 67: 443-462.
25. 2, but not poly(IC), upregulates dopamine D2 receptors in retinoic acid differentiated SH-SY5Y neuroblastoma. Synapse 62: 70-73.
26. Lee SH, Kim YM, Yajima S, Ha JM, Ha BJ, Kim OS, Ohsawa K, Mouradian MM. 2003. Genomic organization and promoter characterization of the murine dopamine receptor regulating factor (DRRF) gene. Gene 304: 193-199.
27. Leist M, Raab B, Maurer S, Rosick U, Brigelius-Flohe R. 1996. Conventional cell culture media do not adequately supply cells with antioxidants and thus facilitate peroxide-induced genotoxicity. Free Radic Biol Med 21: 297-306.
28. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. 1990. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 28: 535-539.
29. Marchese G, Bartholini F, Ruiu S, Casti P, Saba P, Gessa G, Pani L. 2002. Effect of the amisulpride isomers on rat catalepsy. Eur J Pharmacol 444: 69-74.
30. Molina-Jimenez MF, Sanchez-Reus MI, Andres D, Cascales M, Benedi J. 2004. Neuroprotective effect of fraxetin and myricetin against rotenone-induced apoptosis in neuroblastoma cells. Brain Res 1009: 9-16.
31. Morgenstern H, Glazer WM. 1993. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 50: 723-733.
32. Muller MJ, Regenbogen B, Hartter S, Eich FX, Hiemke C. 2007. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res 41: 673-679.
33. Odagaki Y, Dasgupta S, Fuxe K. 1995. Additivity and non-additivity between dopamine-, norepinephrine-, carbachol- and GABA-stimulated GTPase activity. Eur J Pharmacol 291: 245-253.
34. Packer L, Tritschler HJ. 1996. α-Lipoic acid: The metabolic antioxidant. Free Radic Biol Med 20: 625-626.
35. Packer L, Witt EH, Tritschler HJ. 1995. α-Lipoic acid as a biological antioxidant. Free Radic Biol Med 19: 227-250.
36. Packer L, Roy S, Sen CK. 1997. α-Lipoic acid: A metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol 38: 79-101.
37. Pai BN, Janakiramaiah N, Gangadhar BN, Ravindranath V. 1994. Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biol Psychiatry 36: 489-491.
38. Paulson GW. 2005. Historical comments on tardive dyskinesia: A neurologist's perspective. J Clin Psychiatry 66: 260-264.
39. Pillai A, Parikh V, Terry AV, Jr., Mahadik SP. 2007. Long-term antipsychotic treatments and crossover studies in rats: Differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 41: 372-386.
40. Robinson CE, Keshavarzian A, Pasco DS, Frommel TO, Winship DH, Holmes EW. 1999. Determination of protein carbonyl groups by immunoblotting. Anal Biochem 266: 48-57.
41. Rojo AI, Salinas M, Martin D, Perona R, Cuadrado A. 2004. Regulation of Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-κB. J Neurosci 24: 7324-7334.
42. Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD, Neve R, Ratan RR. 2003. Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci 23: 3597-3606.
43. Sagara Y. 1998. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 71: 1002-1012.
44. Schroder J, Silvestri S, Bubeck B, Karr M, Demisch S, Scherrer S, Geider FJ, Sauer H. 1998. D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: A follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment. Biol Psychiatry 43: 660-665.
45. Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, Snyder SH. 2009. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci USA 106: 5171-5176.
46. Shaul U, Ben-Shachar D, Karry R, Klein E. 2003. Modulation of frequency and duration of repetitive magnetic stimulation affects catecholamine levels and tyrosine hydroxylase activity in human neuroblastoma cells: Implication for the antidepressant effect of rTMS. Int J Neuropsychopharmacol 6: 233-241.
47. Shay KP, Moreau RF, Smith EJ, Hagen TM. 2008. Is α-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity. IUBMB Life 60: 362-367.
48. Shivakumar BR, Ravindranath V. 1993. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J Pharmacol Exp Ther 265: 1137-1141.
49. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, Seeman P. 2000. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study. Psychopharmacology (Berl) 152: 174-180.
50. Soares KV, McGrath JJ. 1999. The treatment of tardive dyskinesia-a systematic review and meta-analysis. Schizophr Res 39: 1-16; discussion 17-18.
51. Stadtman ER. 1990. Metal ion-catalyzed oxidation of proteins: Biochemical mechanism and biological consequences. Free Radic Biol Med 9: 315-325.
52. Tenback D, van Harten P, Slooff C, van Os J. 2010. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol 24: 1031-1035.
53. Thaakur S, Himabindhu G. 2009. Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats. J Neural Transm 116: 807-814.
54. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. 1998. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 155: 1207-1213.
55. Wang J, Miller JC, Friedhoff AJ. 1997. Differential regulation of D2 receptor gene expression by transcription factor AP-1 in cultured cells. J Neurosci Res 50: 23-31.
56. Yao JK, Reddy R, McElhinny LG, van Kammen DP. 1998. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 32: 385-391.